Blog

Sep 4, 2024, 14:32

Meet the speakers of CityU – AFCR Symposium – Daniel Johnson

CityU-AFCR Symposium on Precision Medicine and Digital Medicine will go on from 12-13 September as part of BIOHK2024.

The symposium will showcase presentations by BRACE award winners and experts in precision medicine, providing a dynamic platform for the exchange of innovative ideas and fostering a collaborative environment for advancements in the biotechnology field.

Symposium

One of the Speakers is Daniel Johnson

Daniel Johnson, PhD, is Professor and Vice Chair of Research in the Department of Otolaryngology – Head and Neck Surgery (OHNS) at the University of California, San Francisco. He obtained a bachelor of science in chemistry and a bachelor of arts in mathematics, both from North Park University in Chicago, Illinois.

Dr. Johnson earned his MA and PhD in molecular biology from Princeton University, followed by a postdoctoral fellowship at the University of California, San Francisco. Prior to joining UCSF OHNS Department in 2016, Dr. Johnson was a Professor in the Division of Hematology/Oncology, Department of Medicine, and Department of Pharmacology and Chemical Biology at the University of Pittsburgh, Pennsylvania. Dr. Johnson was also the Scientific Director of the Acute Leukemia Working group at the University of Pittsburgh Cancer Institute.

Dr. Johnson has over 120 publications and is Editor of two books, entitled “Cell Death Signaling in Cancer Biology and Treatment” and “Targeting Cell Survival Pathways to Enhance Response to Chemotherapy”. He has maintained continuous NIH funding as a principal investigator since 1995, and has served as a standing member for both NIH and ACS study sections. Dr. Johnson continues to play an active role on multiple review panels for the NIH, VA, and other granting agencies, and serves on the Board of Scientific Counselors for NIH NIDCD.

Since 2001 he has served as a Section Editor for Leukemia, the top-ranked journal for hematologic malignancies, and has also served as Editor for Cancer Research and Oncology Research. Dr. Johnson places a high priority on translating findings from his lab to the clinic, and has facilitated the development of clinical trials in both leukemia and head and neck cancer.

Dr. Johnson’s research is focused on understanding the molecular mechanisms that contribute to the origin and progression of head and neck squamous cell carcinoma (HNSCC), and the development of novel therapeutic agents and strategies for this disease. He is particularly interested in combating the intrinsic and acquired resistance to anti-cancer agents that characterizes the majority of HNSCC patient tumors.

During CityU – AFCR Symposium Daniel Johnson will speak about a topic named ‘Precision Medicine for Fanconi Anemia-Associated Head and Neck Cancer ‘ on September 12.

For more information about CityU-AFCR Symposium visit oncodaily.com